Latest Headlines

  1. Synthego Announces Entry Into Molecular Biology And Clinical Diagnostic Reagents Market 1/13/2026

    Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego's significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality, reliable reagents designed to accelerate the development and deployment of cutting-edge diagnostic tests.

  2. Freenome Announces Expanded Artificial Intelligence And Deep Learning Initiatives Accelerated By NVIDIA, To Advance Personalized Multi-Cancer Detection 1/12/2026

    Freenome today announced an initiative to advance its blood-based early cancer screening program by leveraging NVIDIA deep learning technology and expertise to improve the recognition of cancer-specific patterns in the blood at the disease’s earliest stages.

  3. Alamar Biosciences Announces Launch Of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection In Alzheimer's Disease Research 1/12/2026

    Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay.

  4. 10x Genomics To Advance Research In Diagnostic Applications Of Tumor Single Cell And Spatial Profiling 1/12/2026

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression.

  5. Truvian Health Rapidly Expands TruVerus Menu With FDA Clearances For Cardiovascular, Liver, And Core Metabolic Health Tests 1/12/2026

    Truvian Health (“Truvian”), a transformational diagnostics company redefining healthcare, today announced it has received 510(k) clearances (K251091, K251074, K251157) from the U.S. Food and Drug Administration (FDA) for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.

  6. Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI To Advance Scientific Instrumentation And Accelerate Laboratory Performance 1/12/2026

    Thermo Fisher Scientific Inc. the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale.

  7. Alpenglow Biosciences And PathNet Form Strategic Partnership To Advance National Platform For 3D AI Cancer Diagnostics 1/8/2026

    Alpenglow Biosciences, the leader in clinical-grade 3D digital pathology and AI-powered spatial analytics, and PathNet, one of the nation’s foremost pathology laboratories and largest independent urologic oncology pathology networks, today announced a strategic partnership to develop, validate, and commercialize 3D AI-enabled diagnostic tests for prostate and bladder cancer.

  8. NAMSA Announces Strategic Acquisition Of Select Assets Of The Early Development Medical Device Testing Business Of Labcorp 1/8/2026

    NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services.

  9. Prolytix Expands Capabilities In Thrombosis And Hemostasis Testing 1/8/2026

    Prolytix, a U.S.-based leader in bioanalytical and protein characterization services, announces it has acquired 60 validated assays previously owned by Hemostasis Reference Laboratory (HRL).

  10. Inspira Outlines Strategic Vision And Transaction Framework For Breast Cancer Liquid Biopsy Expansion 1/8/2026

    Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company’s core respiratory and life-support technologies.